22nd Century (XXII)
NASDAQ:XXII
Want to see XXII full AI Analyst Report?
XXII Stock Chart & Stats
$0.76
-$0.08(-1.39%)
At close: 4:00 PM EST
$0.76
-$0.08(-1.39%)
Day’s Range― - ―
52-Week Range$0.51 - $382.95
Previous CloseN/A
Volume40.32K
Average Volume (3M)2.49M
Market Cap
$2.99M
Enterprise Value-$8.60M
Total Cash (Recent Filing)$9.54M
Total Debt (Recent Filing)$841.00K
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-214.80
Shares Outstanding4,455,649
10 Day Avg. Volume328,967
30 Day Avg. Volume2,485,312
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.30
P/FCF Ratio-0.25
Enterprise Value/Market Cap-2.88
Enterprise Value/Revenue-0.97
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$32.50M
Bulls Say, Bears Say
Bulls Say
Regulatory Differentiation (FDA-authorized VLN)FDA authorization and scientific recognition create a durable regulatory moat for the company's VLN product, enabling unique market positioning versus incumbents, facilitating retailer and partner acceptance, and supporting long-term adoption as public-health-aligned policies evolve.
Improved Balance Sheet And Low LeverageMaterial de-leveraging and positive equity provide durable financial flexibility to fund commercialization and product rollout, absorb operating volatility, and reduce solvency risk while executing the multi-quarter distribution and marketing plan.
Retail Distribution Expansion And Commercial TractionConcrete retail wins and a clear outlet expansion target create a lasting commercial runway: broader shelf presence scales brand awareness, concentrates marketing ROI, and builds recurring wholesale channels that support multi-quarter revenue growth if execution continues.
Bears Say
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow means the business cannot self-fund growth today; reliance on external capital constrains long-term planning, limits investment pacing, and raises execution risk over the coming 2–6 months if cash generation doesn't turn positive.
Ongoing Negative Gross Profit And Operating LossesContinued negative gross profit indicates core unit economics are not yet sustainable; even with revenue growth, the company must materially improve pricing, mix, or cost structure to reach durable profitability and margins that justify scaling sales investments.
Dependence On Dilutive External FinancingLarge preferred financings with conversion and warrant features signal ongoing funding need; such structures provide liquidity but introduce dilution and investor protections that can limit common equity upside and reflect structural dependence on capital markets.
22nd Century News
XXII FAQ
What was 22nd Century’s price range in the past 12 months?
22nd Century lowest stock price was $0.51 and its highest was $382.95 in the past 12 months.
What is 22nd Century’s market cap?
22nd Century’s market cap is $2.99M.
When is 22nd Century’s upcoming earnings report date?
22nd Century’s upcoming earnings report date is Aug 19, 2026 which is in 91 days.
How were 22nd Century’s earnings last quarter?
22nd Century released its earnings results on May 07, 2026. The company reported -$5.07 earnings per share for the quarter, missing the consensus estimate of N/A by -$5.07.
Is 22nd Century overvalued?
According to Wall Street analysts 22nd Century’s price is currently Overvalued.
Does 22nd Century pay dividends?
22nd Century does not currently pay dividends.
What is 22nd Century’s EPS estimate?
22nd Century’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 22nd Century have?
22nd Century has 4,455,649 shares outstanding.
What happened to 22nd Century’s price movement after its last earnings report?
22nd Century reported an EPS of -$5.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.353%.
Which hedge fund is a major shareholder of 22nd Century?
Currently, no hedge funds are holding shares in XXII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
22nd Century
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
XXII Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed cautious optimism: management reported clear early commercial progress with sequential revenue growth, gross loss improvement, strategic retail distribution wins, regulatory validation (FDA authorization) and a stable cash position. However, material challenges remain — operating losses and negative adjusted EBITDA widened, profitability is below targets, low-margin contracts persist, and retail adoption is uneven. Management plans focused investments in marketing and distribution with a target of ~5,000 outlets by year-end, but execution risk and competitive headwinds mean near-term results may continue to be pressured.View all XXII earnings summariesTechnical Analysis
Universal
―
Turning Point Brands
―
Greenlane Holdings
―
Kaival Brands Innovations Group
―
Ispire Technology, Inc.
―
Ownership Overview
5.68% Insiders
0.10% Mutual Funds
1.14% Other Institutional Investors
93.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---